Hormone Replacement Therapy
Other Therapy Areas
Explore diabetes
Explore obesity
Explore rare bleeding disorders
Explore growth-related disorders
Explore hormone replacement therapy
Medical Information | Non-US Health Care Professionals
Account Settings
Sign Out
Sign In | Create Account
  • Sign In
    Create Account
    • Account Settings
    • Sign Out
    Other Therapy Areas
    Medical Information
    Non-US Health Care Professionals
Vagifem® (estradiol vaginal inserts) 10 mcg logo
Important Safety Information | Patient Site
Prescribing Information
Vagifem® (estradiol vaginal inserts) 10 mcg logo

Vagifem® is an estrogen (estradiol) indicated for the treatment of atrophic vaginitis due to menopause.

Prescribing Information
Important Safety Information | Patient Site

The therapeutic goal should be to use the most appropriate, often lowest, effective dose of systemic estrogen therapy consistent with treatment goals.1

Dosing

Patients should take Vagifem® 10 mcg in a two-step dosing regimen.2

Patients should take Vagifem® 10 mcg in a two-step dosing regimen.2

  • Initial dose: one tablet inserted intravaginally once daily for two weeks
  • Continued dose: one tablet inserted intravaginally twice weekly—for example, Tuesday and Friday

Request Samples

Vagifem® Dosing Chart
Preloaded Vagifem® Applicator

Preloaded applicators2

Preloaded applicators2

The preloaded, single-use Vagifem® 10 mcg applicators come individually packaged in a blister pack and should be discarded after each use.2

The preloaded, single-use Vagifem® 10 mcg applicators come individually packaged in a blister pack and should be discarded after each use.2

Request product samples

Novo Nordisk provides access to complimentary prescription medicine samples to eligible practitioners for appropriate patients. You may place your order through the Novo Nordisk Sample Portal.

Desktop monitor

Mobile device

Support for mobile devices is currently limited. Please use a desktop computer or tablet to place your orders. We apologize for the inconvenience.

Launch Sample Portal

(Requires a novoMEDLINKTM account)

(Requires a novoMEDLINKTM account)

How to order
Laptop Illustration

Samples are available for this producta

You must be a licensed practitioner who can legally prescribe medication in your state to request Novo Nordisk samples.

You may submit a request once a month.

aSamples for other therapeutic areas may also be available.

Vagifem® Package

Vagifem® 10 mcg

Order your samples with 3 easy steps

1.

2.

3.

Launch the Sample Portal

Launch the Novo Nordisk Sample Portal and if prompted, sign in with your novoMEDLINKTM account.

Sample Request Illustration

Choose your medication samples

Choose your preferred samples and quantities, and then tap or click “Next.”

Sample Request Illustration

Confirm your order details

Confirm your preferences, provide a digital signature and tap or click “Next.”

Sample request illustration
Launch Sample Portal

Important Safety Information

WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, PROBABLE DEMENTIA, and BREAST CANCER

Estrogen-Alone Therapy

Endometrial Cancer

There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. Adding a progestogen to estrogen therapy has been shown to reduce the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer. Perform adequate diagnostic measures, including directed or random endometrial sampling when indicated, to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital bleeding.

Cardiovascular Disorders and Probable Dementia

The Women’s Health Initiative (WHI) estrogen-alone substudy reported increased risks of stroke and deep vein thrombosis (DVT) in postmenopausal women (50 to 79 years of age) during 7.1 years of treatment with daily oral conjugated estrogens (CE) [0.625 mg]-alone, relative to placebo.

The WHI Memory Study (WHIMS) estrogen-alone ancillary study of WHI reported an increased risk of developing probable dementia in postmenopausal women 65 years of age and older during 5.2 years of treatment with daily CE (0.625 mg)-alone, relative to placebo. It is unknown whether this finding applies to younger postmenopausal women.

Do not use estrogen-alone therapy for the prevention of cardiovascular disease or dementia.

Only daily oral 0.625 mg CE was studied in the estrogen-alone substudy of the WHI. Therefore, the relevance of the WHI findings regarding adverse cardiovascular events and dementia to lower CE doses, other routes of administration, or other estrogen-alone products is not known. Without such data, it is not possible to definitively exclude these risks or determine the extent of these risks for other products. Discuss with your patient the benefits and risks of estrogen-alone therapy, taking into account her individual risk profile.

Prescribe estrogens with or without progestogens at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.

Estrogen Plus Progestin Therapy

Cardiovascular Disorders and Probable Dementia

The WHI estrogen plus progestin substudy reported increased risks of pulmonary embolism (PE), DVT, stroke, and myocardial infarction (MI) in postmenopausal women (50 to 79 years of age) during 5.6 years of treatment with daily oral CE (0.625 mg) combined with medroxyprogesterone acetate (MPA) [2.5 mg], relative to placebo.

The WHIMS estrogen plus progestin ancillary study of the WHI reported an increased risk of developing probable dementia in postmenopausal women 65 years of age and older during 4 years of treatment with daily CE (0.625 mg) combined with MPA (2.5 mg), relative to placebo. It is unknown whether this finding applies to younger postmenopausal women.

Do not use estrogen plus progestogen therapy for the prevention of cardiovascular disease or dementia.

Breast Cancer

The WHI estrogen plus progestin substudy demonstrated an increased risk of invasive breast cancer.

Only daily oral 0.625 mg CE and 2.5 mg MPA were studied in the estrogen plus progestin substudy of the WHI. Therefore, the relevance of the WHI findings regarding adverse cardiovascular events, dementia and breast cancer to lower CE plus other MPA doses, other routes of administration, or other estrogen plus progestogen products is not known. Without such data, it is not possible to definitively exclude these risks or determine the extent of these risks for other products. Discuss with your patient the benefits and risks of estrogen plus progestogen therapy, taking into account her individual risk profile.

Prescribe estrogens with or without progestogens at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.

Indication and Usage

Vagifem® (estradiol vaginal inserts) is an estrogen indicated for the treatment of atrophic vaginitis due to menopause.

Important Safety Information cont.

Contraindications

  • Undiagnosed abnormal genital bleeding
  • Breast cancer or a history of breast cancer
  • Estrogen-dependent neoplasia
  • Active DVT, PE, or history of these conditions
  • Active arterial thromboembolic disease (for example, stroke or MI), or a history of these conditions
  • Known anaphylactic reaction, angioedema, or hypersensitivity to Vagifem®
  • Hepatic impairment or disease
  • Protein C, protein S, or antithrombin deficiency, or other known thrombophilic disorders

Warnings and Precautions

  • Risks from systemic absorption: Vagifem® is intended only for vaginal administration. Systemic absorption occurs with the use of Vagifem®. The warnings, precautions, and adverse reactions associated with the use of systemic estrogen-alone therapy should be taken into account.
  • Cardiovascular Disorders: Immediately discontinue estrogen with or without progestogen therapy if PE, DVT, stroke or MI occur or are suspected.
  • Malignant Neoplasms: The CE plus MPA substudy of WHI reported a statistically non-significant increased risk of ovarian cancer with the use of estrogen plus progestin. A meta-analysis of 17 prospective and 35 retrospective studies found that woman who used hormonal therapy for menopausal symptoms had an increased risk for ovarian cancer.
  • Gallbladder disease: A 2-4 fold increase in the risk of gallbladder disease requiring surgery in postmenopausal women receiving estrogens has been reported.
  • Discontinue Vagifem® if severe hypercalcemia, visual abnormalities (sudden loss of vision, sudden onset of proptosis, diplopia, or migraine), severe hypertriglyceridemia, cholestatic jaundice or medically concerning fluid retention occurs.
  • Exacerbation of Hypothyroidism: Monitor thyroid function in women on thyroid hormone replacement therapy who are also receiving estrogens because estrogen leads to increased thyroid-binding globulin (TBG) levels.
  • Local abrasion: A few cases of local abrasion induced by the Vagifem® applicator have been reported.

Adverse Reactions

  • The most common adverse reactions (incidence ≥5 percent) with Vagifem® are back pain, vulvovaginal pruritus, vulvovaginal mycotic infection, and diarrhea.

Drug Interactions

  • Inducers and inhibitors of CYP3A4 may affect estrogen drug metabolism and decrease or increase the estrogen plasma concentration.

Please click here for Vagifem® Prescribing Information, including Boxed Warning.

References

  1. North American Menopause Society. The 2017 hormone therapy position statement of The North American Menopause Society. Menopause: The Journal of the North American Menopause Society. 2017;24(7):728-753.
  2. Vagifem [package insert]. Princeton, NJ Novo Nordisk FemCare AG; 2019.
Hormone Replacement Therapy
Other Therapy Areas
Explore diabetes
Explore obesity
Explore rare bleeding disorders
Explore growth-related disorders
Explore hormone replacement therapy
Explore diabetes
Explore obesity
Explore rare bleeding disorders
Explore growth-related disorders
Explore hormone replacement therapy

Vagifem® is a registered trademark of Novo Nordisk Health Care AG.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
All other trademarks, registered or unregistered, are the property of their respective owners.
Non-US Health Care Professionals, please go to www.novonordiskpro.com.

Legal Notice | Privacy Policy | Cookie Policy | Contact Us |
novonordisk-us.com    
© 2022 Novo Nordisk All rights reserved. US22HCP00081 November 2022

Quick links

Diabetes product information

Diabetes samples

Obesity product information

Obesity samples